Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NGNE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNeurogene appoints Christina Shafer as Chief Commercial Officer, adds CFO to Board
Filed April 20, 2026 · Period ending April 20, 2026 · ~1 min read
Key Changes
-
medium
Christina Shafer appointed Chief Commercial Officer, a new executive role signaling potential preparation for product commercialization or scaling of commercial operations.
Item 8.01 press release view on EDGAR → -
low
Board expanded from six to seven directors; President & CFO Christine Mikail appointed as Class II director through 2028 annual meeting.
Item 5.02 verify on EDGAR → -
low
Mikail brings 20+ years biotech/pharma experience across strategy, business development, operations, and finance; has been with Neurogene since 2019.
Item 5.02 verify on EDGAR → -
low
Mikail will receive no additional compensation for Board service beyond existing executive pay as President and CFO.
Item 5.02 verify on EDGAR →
Summary
Neurogene announced two leadership changes on April 20, 2026. The company appointed Christina Shafer as Chief Commercial Officer, a newly created executive position that suggests Neurogene may be preparing to commercialize products or expand its commercial capabilities. This is the more material development for investors, as it indicates potential progression toward revenue-generating activities.
Separately, the Board of Directors expanded from six to seven seats and appointed Christine Mikail, the company's current President and CFO, to fill the new position. Mikail has been with Neurogene since 2019 and was promoted to her current dual role in December 2023. She will serve as a Class II director through the 2028 annual meeting and will not receive separate director compensation.
This is a routine governance action that adds an insider perspective to the Board. Investors should watch for announcements about commercial strategy, product launch timelines, or regulatory milestones that would clarify why Neurogene is building out its commercial leadership now.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Neurogene filed an 8-K attaching a press release dated April 20, 2026; no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press Release dated April 20, 2026
The 8-K references an attached press release dated April 20, 2026 (Exhibit 99.1), but the filing body does not disclose the content or subject matter of that release. Without the exhibit text, the nature and materiality of the disclosed event cannot be determined from this filing alone.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 3 minor / wording changes
Added in current filing · verify on EDGAR →
Effective as of April 20, 2026, the Board of Directors (the “Board”) of Neurogene Inc. (the “Company”), upon recommendation of the Board's Nominating and Corporate Governance Committee (the "Nominating Committee"), took action pursuant to the Company's Amended and Restated Bylaws to expand the Board to seven directors and appoint Christine Mikail, the Company’s President and Chief Financial Officer, to fill the vacancy created by that expansion. Ms. Mikail was appointed as a Class II director for a term that will expire at the 2028 annual meeting of the Company's stockholders.
The Board expanded from six to seven directors and appointed Christine Mikail, the company's current President and CFO, to fill the new seat. Ms. Mikail will serve as a Class II director with a term expiring at the 2028 annual stockholder meeting. This is a routine governance action adding an existing executive to the Board.
Added in current filing · verify on EDGAR →
Ms. Mikail has served as the Company’s President and Chief Financial Officer since December 2023, and as President and Chief Financial Officer of the Company’s wholly owned operating subsidiary, Neurogene Inc., a Nevada corporation (“Neurogene OpCo” and together with the Company, “Neurogene”), since September 2019 and as a member of the board of directors of Neurogene OpCo since December 2023. Ms. Mikail leads Corporate Strategy and Business Development, Portfolio Management, Operations, and Finance at the Company. Ms. Mikail brings over two decades of experience supporting biotechnology and pharmaceutical companies in corporate strategy and business development, operations, legal and finance capacities.
Christine Mikail has been with Neurogene since September 2019 and was promoted to President and CFO in December 2023. She oversees corporate strategy, business development, portfolio management, operations, and finance, bringing over 20 years of biotech and pharma experience across multiple functional areas.
Added in current filing · verify on EDGAR →
As an executive of the Company, Ms. Mikail will not receive any additional compensation for her role as a director of the Company.
Ms. Mikail will not receive separate director compensation beyond her existing executive compensation as President and CFO. This is standard practice when sitting executives join the board.
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
the Company issued a press release announcing the appointment of Christina Shafer as Chief Commercial Officer of the Company
Neurogene appointed Christina Shafer as Chief Commercial Officer. This is a new executive leadership position focused on commercial strategy and operations. The appointment signals the company may be preparing for product commercialization or scaling commercial activities.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
the appointment of Christine Mikail to the Board to fill a newly created vacancy on the Board
Christine Mikail was appointed to the Board of Directors to fill a newly created vacancy, expanding the Board's size. Board expansions typically bring additional expertise or perspectives to governance and strategic oversight.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify